Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

More efficient diagnostic tools are not always used for neuropathy patients

Researchers at the University of Michigan analyzed the tremendous cost of diagnosing peripheral neuropathy and found that less expensive, more effective tests are less likely to be used.

24 Jan 2012

Researchers analyze tremendous cost of peripheral neuropathy diagnosis

Researchers at the University of Michigan analyzed the tremendous cost of diagnosing peripheral neuropathy and found that less expensive, more effective tests are less likely to be used.

24 Jan 2012

Power3, Amarantus sign license agreement for NuroPro Blood Test for Parkinson's

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro Blood Test as it relates to Parkinson's disease diagnosis.

24 Jan 2012

Scientists reveal structure of cellular protein degradation machinery

Defective proteins that are not disposed of by the body can cause diseases such as Alzheimer's or Parkinson's. Scientists at the Max Planck Institute (MPI) of Biochemistry recently succeeded in revealing the structure of the cellular protein degradation machinery (26S proteasome) by combining different methods of structural biology.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Possible link between vascular lesions and Alzheimer's disease

Approximately 20 percent of all stroke survivors will develop cognitive problems later in life, including vascular dementia. Experts with the Methodist Neurological Institute in Houston say recent research showing a possible link between vascular lesions and Alzheimer's disease is yet another reason to be more vigilant in our efforts to prevent a stroke.

24 Jan 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

Cedars-Sinai's annual Brainworks program to take place on Feb. 13

Taking turns gazing into a surgical microscope, 130 seventh- and eighth-graders from Los Angeles area schools will see a phantom skull and perform virtual surgery - and many could catch a glimpse of the future.

20 Jan 2012

Banner Alzheimer's Institute presents results from Navidea AZD4694 study at 6th Annual HAI

Navidea Biopharmaceuticals, Inc. today announced that the Banner Alzheimer's Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea's late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL.

20 Jan 2012

Viewpoints: The 'need' to repeal CLASS; Squaring Romney's poverty and tax promises

As a physician, I treated hundreds of patients who needed long-term care, including ones with Alzheimer's. More than 13.5 million seniors could have this disease by 2040. Middle-class families remain dangerously unprepared for these costs. Some people will likely spend more than $100,000 on care. The fictional CLASS daily benefit of $50 per day won't cover this. I urge my House and Senate colleagues to support this CLASS repeal.

19 Jan 2012

Vitamin D could prevent age related eye degeneration: Study

A new study showed that increased vitamin D intake can help to prevent age-related diseases, in particular loss of vision and blindness.

18 Jan 2012

Pfizer and Medivation drop further testing of failed Alzheimer’s drug

A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.

18 Jan 2012

Slow-wriggling alpha-synuclein proteins cause Parkinson's disease

Imagine if doctors could spot Parkinson's disease at its inception and treat the protein that triggers it before the disease can sicken the patient.

18 Jan 2012

Defects in mitochondria lead to devastating neurodegenerative disease

A devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk has been traced to defects in mitochondria, the 'batteries' or energy-producing power plants of cells. This finding by a team of researchers, led by investigators from the Montreal Neurological Institute and Hospital - The Neuro- at McGill University, was published in this week's issue of the Proceedings of the National Academy of Sciences of the USA.

18 Jan 2012

U.S. readies plan to fight Alzheimer's

The government is setting what it calls an ambitious goal for Alzheimer's disease: Development of effective ways to treat and prevent the mind-destroying illness by 2025. The Obama administration is developing the first National Alzheimer's Plan to find better treatments for the disease and offer better day-to-day care for those afflicted.

18 Jan 2012

Pfizer, Medivation report results from dimebon Phase 3 trial on AD

Medivation, Inc. and Pfizer Inc. today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease.

18 Jan 2012

Georgia Tech findings advance glaucoma research

Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent. New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.

18 Jan 2012

Vitamin D supplements can fight against age-related macular degeneration

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have found that vitamin D reduces the effects of ageing in mouse eyes and improves the vision of older mice significantly. The researchers hope that this might mean that vitamin D supplements could provide a simple and effective way to combat age-related eye diseases, such as macular degeneration (AMD), in people.

17 Jan 2012

AAN neurologist receives prestigious award at Palatucci Advocacy Leadership Forum

The American Academy of Neurology(AAN) has named neurologist Constantine Moschonas, MD, of Scottsdale, Ariz., as the AAN Donald M. Palatucci Advocacy Leadership Forum Advocate of the Year. Moschonas received his award at the Palatucci Advocacy Leadership Forum on January 14, 2012, in Austin, Texas, for his outstanding work in raising awareness about brain diseases such as Alzheimer's disease, stroke, autism, Parkinson's disease and multiple sclerosis.

17 Jan 2012

Arm sling or cast use after injury may cause rapid brain shift

Using a sling or cast after injuring an arm may cause your brain to shift quickly to adjust, according to a study published in the January 17, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

17 Jan 2012